A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs P 1037 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Acronyms CLEAN-CF
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 27 Apr 2016 Results published in Vertex media release.
    • 12 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top